Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

Hinge Health, the world’s #1 Digital Musculoskeletal Clinic™, has acquired wrnch, developer of the leading computer vision platform for measuring human motion. wrnch’s three-dimensional motion-tracking technology enables the same precise tracking of full-body movement used by elite athletes and the motion picture industry.

Hinge Health now has the largest computer vision team in digital health.

This acquisition underlines the commitment of Hinge Health, the market leader in musculoskeletal (MSK) care, to pioneering better ways of delivering care. Movement-tracking technologies, such as computer vision and motion sensors, enable Hinge Health’s clinical care team to deliver the most responsive and personalized whole-body approach to MSK care, improving outcomes and member experience while reducing costs.

Combining motion sensors and computer vision further burnishes Hinge Health’s digital physical therapy solution as the most comprehensive on the market, uniquely enabling the following:

  • Motion assessments to objectively measure a patient’s functional ability across strength, flexibility, balance, and endurance to inform care plan personalization.
  • Expanded exercise tracking as computer vision and motion sensors together enable the widest range and measurement of full-body exercises, including yoga and aerobics.
  • Enhanced clinical care programs that improve rehab of difficult-to-treat areas, such as the head, neck, and hands, by tracking 87 unique points on the body.

Hinge Health continues to pioneer new standards in personalized MSK care by pairing a comprehensive clinical care team with the industry’s most advanced technology portfolio:

  • Computer vision and motion sensors for exercise therapy and motion assessments.
  • Hinge Health Enso, a groundbreaking wearable technology for immediate noninvasive and nonaddictive pain relief.
  • HingeConnect for bridging the gap between in-person and digital MSK care and enabling real-time interventions by integrating health data with 750,000+ providers.

“We built wrnch into the world’s leading artificial intelligence and computer vision R&D lab to understand human motion, shape, and intent,” said Dr. Paul A. Kruszewski, founder and CEO of wrnch. “I’m so excited to combine our artificial intelligence technology with Hinge Health’s Digital MSK Clinic to improve clinical outcomes for millions of members.”

Hinge Health cofounder and CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version